Cargando…
Ruxolitinib with resminostat exert synergistic antitumor effects in Cutaneous T-cell Lymphoma
BACKGROUND: The combination of JAK/STAT and HDAC inhibitors exerted beneficial effects in haematological malignancies, presenting promising therapeutic CTCL targets. We aim to investigate the efficacy of JAK1/2i ruxolitinib in combination with HDACi resminostat in CTCL in vitro. MATERIAL & METHO...
Autores principales: | Karagianni, Fani, Piperi, Christina, Mpakou, Vassiliki, Spathis, Aris, Foukas, Periklis G., Dalamaga, Maria, Pappa, Vasiliki, Papadavid, Evangelia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7951910/ https://www.ncbi.nlm.nih.gov/pubmed/33705488 http://dx.doi.org/10.1371/journal.pone.0248298 |
Ejemplares similares
-
Combination of Resminostat with Ruxolitinib Exerts Antitumor Effects in the Chick Embryo Chorioallantoic Membrane Model for Cutaneous T Cell Lymphoma
por: Karagianni, Fani, et al.
Publicado: (2022) -
Synergistic inhibitory effects of low-dose decitabine in combination with bortezomib in the AML cell line Kasumi-1
por: Mpakou, Vassiliki, et al.
Publicado: (2021) -
Apoptosis Induction and Gene Expression Profile Alterations of Cutaneous T-Cell Lymphoma Cells following Their Exposure to Bortezomib and Methotrexate
por: Mpakou, Vassiliki, et al.
Publicado: (2017) -
Predominant Role of mTOR Signaling in Skin Diseases with Therapeutic Potential
por: Karagianni, Fani, et al.
Publicado: (2022) -
Psoriatic Insomnia: A Subjective and Objective Sleep Evaluation
por: VLAMI, Katerina, et al.
Publicado: (2023)